查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984183

下一代乳癌诊断和筛检市场：按产品、检测类型、分期、应用和最终用户划分—2026-2032年全球市场预测

Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计下一代乳癌诊断和筛检市场在 2025 年的价值为 74.7 亿美元，在 2026 年增长到 80.2 亿美元，到 2032 年达到 128 亿美元，复合年增长率为 7.99%。

主要市场统计数据
基准年 2025 74.7亿美元
预计年份：2026年 80.2亿美元
预测年份 2032 128亿美元
复合年增长率 (%) 7.99%

这本入门书籍展望了下一代乳癌诊断的未来前景，并将其置于临床实践、技术整合和策略实施的必要性背景下进行讨论。

在乳癌诊断和筛检领域，技术、监管和临床要素正以前所未有的程度相互交织，重新定义着该疾病的检测、表征和管理方式。影像学、分子检测、数位病理学和微创切片检查等领域的最新创新，已将临床工作流程从单一模式转变为以准确性、速度和以患者为中心的综合诊断路径。如今，临床医生和医疗系统所需的工具不仅能够实现恶性肿瘤的早期发现，还能促进风险分层、预测治疗反应，并在整个治疗过程中进行高效监测。

影像、分子分析、数位病理学和分散式检查等领域的技术进步如何重新定义乳癌的诊断途径和策略重点。

由于多种因素加速了技术应用并重建了竞争优势，这种情况正在改变。影像技术的进步，尤其是在解析度提高、人工智慧 (AI) 影像解读和多模态融合的推动下，正在改善病灶表征并减少以往阻碍诊​​断过程的假阳性结果。同时，分子诊断和液态生物检体调查方法正在推动更精细的肿瘤分析，从而实现分子突变的早期检测和更详细的时间序列监测。数位病理平台和基于云端的工作流程促进了远端专家审查和演算法支持，而植入式感测器和穿戴式装置则为持续监测生理指标和生物标记提供了可能。

基于证据的评估，探讨 2025 年美国关税措施将如何重塑乳癌诊断领域的供应链、筹资策略和创新动态。

美国2025年实施的一系列关税措施的累积影响，正对供应链、采购成本和跨境合作造成复杂的压力，并波及整个诊断和筛检生态系统。诊断设备、成像组件和特殊试剂在生产和分销过程中经常需要跨越多个国家。关税会增加最终成本，并使医院、诊断检查室和专科诊所在选择供应商时更加复杂。为此，采购团队正在审查供应商整合和近岸外包策略，以最大限度地减少对临床营运的干扰，同时保持预算柔软性。

策略性细分洞察揭示了产品阵容、测试方法、临床阶段重点、用例和最终用户概况如何影响诊断技术的采用和优先排序。

基于细分市场的分析揭示了该领域临床需求、技术成熟度和商业性机会的交汇点。对产品系列的分析表明，影像技术在解剖学检测和风险分层中仍然发挥着核心作用，其中乳房X光摄影光摄影、磁振造影（MRI）和乳房超音波各自满足不同的临床需求。乳房X光摄影仍然是大规模筛检的基础，MRI在高风险和緻密型乳房病例中表现出色，超音波有助于病灶定性和引导介入治疗。数位病理平台扩展了诊断处理能力，并实现了演算法分诊。同时，包括微阵列、次世代定序和基于PCR的检测在内的分子诊断技术，提供了个人化治疗选择和微量残存疾病评估所需的分子水平分辨率。植入式感测器和穿戴式装置仍在发展中，但它们是实现连续生理监测的极具前景的手段，而液态生物检体技术则为理解肿瘤基因组分析和动态变化提供了微创方法。

美洲、欧洲、中东、非洲和亚太地区在诊断技术的采用和政策方面存在差异，这决定了获取、报销和部署的优先事项。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的技术应用、报销途径和临床重点产生了显着影响。在美洲，医疗保健系统和保险公司日益鼓励以价值为导向的医疗模式，重视早期发现和精准诊断，这推动了大规模学术医疗中心和私人医疗网络采用整合影像和分子诊断平台。在该地区的部分地区，监管和报销环境支持快速采用具有可靠临床证据支持的创新检测方法，而商业策略通常强调与医院网路和诊断实验室建立合作关係，以确保获得临床病例。

科学差异化、监管策略、伙伴关係和供应链韧性如何决定诊断和筛检解决方案供应商的竞争优势。

诊断和筛检生态系统的竞争动态是由科学差异化、监管进步、策略伙伴关係和商业化敏捷性这四者共同驱动的。领先企业优先考虑端到端价值，将高品质的检测和医疗设备与软体驱动的解读和服务模式相结合，从而减轻临床用户的负担。与学术机构和临床网络的合作能够加速循证医学的产生，并支持其被纳入临床实践指南；而与保险公司和医疗服务提供者的合作则有助于建立报销机制，并在真实的临床环境中检验其绩效。

为诊断创新者和医疗保健系统领导者提供可操作和优先行动方案，以加速采用、降低商业化风险，并使证据与报销途径保持一致。

产业领导者必须采取果断行动，将技术潜力转化为永续的临床和商业性价值。首先，他们应优先考虑整合产品策略，将高品质的诊断方法和医疗设备与分析软体和服务等级协议相结合，从而降低临床医生和检查室采用这些技术所面临的障碍。其次，他们应投资于针对性临床检验，直接解决诊疗路径中的决策点。这不仅应展现分析性能，还应展现其在早期检测、治疗方法选择和长期监测方面的临床效用。第三，他们应透过供应商多元化、关键製造能力的地域分散以及建立紧急库存管理方法来应对关税和贸易波动，从而提高供应链透明度。

我们采用严谨且多方面的调查方法，结合与主要相关人员的对话、临床文献的整合、监管趋势的分析和情境分析，得出了可靠的见解。

本分析所依据的研究基于多层次的调查方法，该方法整合了关键相关人员的意见、同行评审的临床文献、监管文件以及诊断服务供应商的营运资讯。主要研究包括对临床医生、检查室管理人员、政策顾问和采购专家进行结构化访谈，以了解实际工作流程的限制、对证据的期望以及推广应用的障碍。次要资讯包括已发布的监管文件、临床指南、技术白皮书和近期学术文章，这些资料被用作技术评估的基础，并用于检验临床效用声明。

全面概述诊断技术的演变，展示整合技术、证据策略和营运韧性如何决定临床和商业性的成功。

乳癌诊断和筛检的发展既反映了技术的成熟，也反映了以价值主导、以患者为中心的医疗体系的系统性重组。影像学、分子检测、数位病理学和分散式检查模式的进步并非孤立的创新，而是构成一个综合诊断生态系统的组成部分，该生态系统支持早期发现、更精准的治疗方法选择和高效的监测。监管预期、报销机制和供应链韧性等实际操作因素，将决定哪些技术能够从「前景广阔」走向「广泛应用」。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：下一代乳癌诊断和筛检市场：按产品/服务划分

  • 数位病理学
  • 医学影像技术
    • 乳腺超音波检查
    • 磁振造影
    • 乳房X光摄影
  • 嵌入式感测器
  • 液态生物检体
  • 分子诊断
    • 微阵列
    • 次世代定序
    • 基于PCR的检测
  • 穿戴式装置

第九章 下一代乳癌诊断与筛检市场：检测类型

  • 基因检测
    • BRCA基因检测
    • 基因组分析
  • 病理检查
    • 细胞学
    • 组织病理学
  • 蛋白质标记检测
    • ER/PR 检测
    • HER2检测

第十章：下一代乳癌诊断与筛检市场：按阶段划分

  • 晚期
    • 第三阶段
    • 第四阶段
  • 早期的
    • 第一阶段
    • 第二阶段

第十一章 下一代乳癌诊断与筛检市场：按应用划分

  • 早期检测
    • 定期乳房X光摄影
    • 自我检查
  • 后续观察
    • 復发
    • 治疗反应
  • 健康检查计划

第十二章 下一代乳癌诊断与筛检市场：依最终用户划分

  • 学术和研究机构
  • 诊断检测实验室
  • 医院
  • 专科诊所

第十三章：下一代乳癌诊断与筛检市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 下一代乳癌诊断与筛检市场：按组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 下一代乳癌诊断和筛检市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国下一代乳癌诊断与筛检市场

第十七章：中国下一代乳癌诊断与筛检市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agendia Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Centogene NV
  • Danaher Corporation
  • Epic Sciences, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF0

The Next-Generation Breast Cancer Diagnostic & Screening Market was valued at USD 7.47 billion in 2025 and is projected to grow to USD 8.02 billion in 2026, with a CAGR of 7.99%, reaching USD 12.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.47 billion
Estimated Year [2026] USD 8.02 billion
Forecast Year [2032] USD 12.80 billion
CAGR (%) 7.99%

A forward-looking primer that situates next-generation breast cancer diagnostics within clinical practice, technology convergence, and strategic adoption imperatives

The diagnostic and screening landscape for breast cancer is undergoing a rare confluence of technological, regulatory, and clinical forces that is redefining how disease is detected, characterized, and managed. In recent years, innovations in imaging, molecular assays, digital pathology, and minimally invasive sampling have shifted clinical workflows away from singular modalities toward integrated diagnostic pathways that emphasize precision, speed, and patient-centric access. Clinicians and health systems now demand tools that not only detect malignancy earlier but also stratify risk, predict treatment response, and enable streamlined monitoring across the continuum of care.

This introduction positions stakeholders to view next-generation diagnostics as more than incremental device or assay improvements. Instead, they represent architectural changes to care delivery: diagnostic data now informs therapeutic choices in near real time, digital platforms enable remote interpretation and triage, and decentralized testing models expand reach beyond traditional hospital systems. As we proceed through this analysis, the emphasis will remain on how technological maturity, clinical validation, reimbursement evolution, and supply chain resilience converge to influence adoption decisions and competitive positioning. Readers should expect evidence-based synthesis that prioritizes actionable implications for clinical, commercial, and policy leaders operating at the intersection of innovation and patient outcomes.

How technological advances in imaging, molecular profiling, digital pathology, and decentralized testing are redefining breast cancer diagnostic pathways and strategic priorities

The landscape is shifting along multiple vectors that collectively accelerate adoption and reconfigure competitive advantage. Advances in imaging technologies-driven by enhanced resolution, artificial intelligence-augmented interpretation, and multimodal integration-are improving lesion characterization and reducing false positives that traditionally burden diagnostic pathways. Concurrently, molecular diagnostics and liquid biopsy methodologies are transforming the granularity of tumor profiling, enabling earlier detection of molecular alterations and richer longitudinal monitoring. Digital pathology platforms and cloud-based workflows are facilitating remote expert review and algorithmic augmentation, while implantable sensors and wearable devices are introducing continuous physiologic and biomarker monitoring possibilities.

These technical shifts are accompanied by systemic changes. Health systems increasingly prioritize value-based outcomes that reward early detection and precise treatment selection, therefore creating incentives to deploy tools that demonstrably reduce unnecessary interventions and improve patient trajectories. Regulatory pathways are evolving to accommodate software as a medical device and genomic assays, which shortens paths to clinical use when supported by robust clinical evidence. At the same time, patient expectations for convenience and information access are pushing screening programs toward decentralized and hybrid models that blend at-home testing with point-of-care diagnostics. Together, these transformative shifts demand that stakeholders rethink product development roadmaps, evidence generation strategies, and commercialization plans to capture emerging opportunities and address new operational challenges.

An evidence-based assessment of how the 2025 United States tariff measures reshape supply chains, procurement strategies, and innovation dynamics in breast cancer diagnostics

The cumulative impact of tariff actions implemented by the United States in 2025 has introduced a complex set of pressures across supply chains, procurement costs, and cross-border collaborations that reverberate through diagnostic and screening ecosystems. Diagnostic instruments, imaging components, and specialized reagents frequently cross multiple borders during manufacture and distribution; tariffs increase landed cost and complicate vendor selection for hospitals, diagnostic laboratories, and specialty clinics. In response, procurement teams are reassessing supplier consolidation and nearshoring strategies to preserve budgetary flexibility while minimizing clinical disruption.

Beyond direct price effects, tariffs have amplified strategic re-evaluations of inventory management and contractual terms. Organizations that previously relied on just-in-time supply models are strengthening buffer stocks for critical reagents and imaging parts, and diagnostic manufacturers are diversifying manufacturing footprints to mitigate tariff exposure. Clinical research activities that depend on international assay kits and instrumentation face elongated timelines due to customs clearance variability, prompting sponsors to redesign trial logistics and localize certain assay processing where feasible.

Furthermore, tariffs influence innovation calculus. Companies that depend on cross-border component sourcing must allocate incremental capital to preserve margins, which can delay investments in validation studies or software enhancements. Conversely, some firms view the environment as an impetus to verticalize manufacturing and invest in domestic capabilities, a move that can accelerate local job creation and regulatory engagement but requires upfront capital and operational maturity. Ultimately, the tariff landscape is reshaping cost structures, partnership models, and operational resilience, encouraging stakeholders to adopt more robust scenario planning and supply-chain transparency.

Strategic segmentation insights revealing how offerings, test modalities, clinical stage focus, application use cases, and end-user profiles shape diagnostic adoption and prioritization

A segmentation-driven view of the field illuminates where clinical need, technological readiness, and commercial opportunity intersect. When offerings are parsed, imaging technologies remain central for anatomical detection and risk stratification, with mammography, magnetic resonance imaging, and breast ultrasound each fulfilling distinct clinical niches; mammography continues as the backbone of population screening, magnetic resonance imaging excels in high-risk and dense-breast contexts, and ultrasound complements both in lesion characterization and guided interventions. Digital pathology platforms are expanding diagnostic throughput and enabling algorithmic triage, while molecular diagnostics-encompassing microarrays, next-generation sequencing, and PCR-based assays-deliver the molecular resolution needed for personalized therapy selection and minimal residual disease assessment. Implantable sensors and wearable devices are nascent but promising vectors for continuous physiologic surveillance, and liquid biopsy technologies provide minimally invasive windows into tumor genomics and dynamics.

Examining test types yields further clarity on clinical workflows and investment priorities. Genetic tests such as BRCA analysis and broader genomic profiling are pivotal in hereditary risk assessment and targeted therapy selection, whereas pathological tests, including cytology and histopathology, remain indispensable for definitive diagnosis and staging. Protein marker testing, notably ER/PR assays and HER2 evaluation, continues to guide therapeutic decision-making and necessitates rigorous assay standardization. Stage-based segmentation differentiates early-stage needs-where routine mammograms and self-exams support early detection and curative intent-from advanced-stage priorities, which focus on monitoring stage III and IV disease for recurrence and treatment response. Application-focused distinctions highlight the divergent requirements of early detection programs, ongoing monitoring for recurrence or therapeutic efficacy, and organized screening programs that prioritize population-level reach and adherence.

Finally, end-user segmentation underscores operational realities: academic and research institutes drive translational validation and complex assay development, diagnostic laboratories scale throughput and ensure quality control, hospitals integrate diagnostics into multidisciplinary care pathways, and specialty clinics deliver focused services with rapid turnaround. Each end user demands tailored evidence, workflow integration, and economic justification, which in turn shapes product design, service models, and commercialization strategies.

Regional diagnostic adoption and policy variance across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access, reimbursement, and deployment priorities

Regional dynamics materially influence technology adoption, reimbursement pathways, and clinical priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, health systems and payers increasingly incentivize value-based approaches that reward early detection and precision diagnostics, propelling adoption of integrated imaging and molecular platforms within large academic centers and private networks. The regulatory and reimbursement environment in parts of the region supports rapid adoption of innovative assays when supported by robust clinical evidence, and commercial strategies frequently emphasize partnerships with hospital networks and diagnostic laboratories to secure clinical volume.

Across Europe, Middle East and Africa, heterogeneity in regulatory regimes and healthcare financing creates a patchwork of adoption pathways. High-income European markets often demonstrate rapid uptake of validated molecular diagnostics and AI-enhanced imaging, while other jurisdictions prioritize access and cost-effectiveness, influencing the balance between population screening programs and targeted high-risk interventions. Regulatory harmonization efforts and cross-border clinical collaborations in the region help streamline multicenter validation studies, yet logistical complexity and variable infrastructure require adaptable deployment models.

The Asia-Pacific region presents a mix of large-scale public screening initiatives and fast-growing private healthcare sectors, with particular emphasis on scalable, cost-efficient technologies that can serve diverse populations. Rapid urbanization and investments in digital health are enabling telepathology and AI-enabled imaging platforms to expand reach, while regional manufacturing hubs are increasingly important for supply chain resilience. Across all regions, localized evidence generation, culturally appropriate patient engagement, and alignment with national screening policies remain critical determinants of long-term uptake.

How scientific differentiation, regulatory strategy, partnerships, and supply-chain resilience combine to define competitive advantage among diagnostic and screening solution providers

Competitive dynamics in the diagnostics and screening ecosystem are driven by the intersection of scientific differentiation, regulatory progress, strategic partnerships, and commercialization agility. Leading organizations prioritize end-to-end value by combining high-quality assays or devices with software-enabled interpretation and service models that reduce friction for clinical users. Collaboration with academic centers and clinical networks accelerates evidence generation and supports guideline inclusion, while alliances with payers and providers help establish reimbursement pathways and real-world performance validation.

Innovation strategies vary: some companies focus on deep specialization, advancing proprietary assay chemistry, sequencing platforms, or sensor technologies to create defensible niches. Others pursue horizontal integration, bundling imaging, molecular, and digital pathology capabilities to offer comprehensive diagnostic solutions. Commercial rigor matters: organizations that invest in robust regulatory strategies, post-market surveillance, and clinician education consistently realize higher adoption rates. Additionally, supply-chain resilience and manufacturing flexibility now function as competitive advantages given recent trade and tariff dynamics, prompting firms to diversify sourcing, localize production, and strengthen distributor relationships. Ultimately, players that align scientific innovation with pragmatic deployment strategies and evidence-led payer engagement position themselves to capture clinical trust and long-term commercial viability.

Practical, prioritized actions for diagnostic innovators and health system leaders to accelerate adoption, de-risk commercialization, and align evidence with reimbursement pathways

Industry leaders must act decisively to convert technological promise into sustainable clinical and commercial value. First, prioritize integrated product strategies that combine high-quality assays or devices with interpretive software and service-level agreements that lower adoption friction for clinicians and laboratories. Second, invest in targeted clinical validation that maps directly to decision points in care pathways; demonstrate not only analytic performance but also clinical utility in early detection, treatment selection, and longitudinal monitoring. Third, strengthen supply-chain transparency by diversifying suppliers, regionalizing critical manufacturing capacity, and establishing contingency inventory practices to manage tariff and trade volatility.

Leaders should also cultivate payer and provider partnerships early in development to align evidence generation with reimbursement expectations and real-world performance measures. Embrace modular commercialization approaches that allow rapid piloting within academic centers and specialty clinics while scaling to larger hospital networks and national screening programs. Finally, invest in workforce and clinician education to ensure new technologies integrate into existing workflows without imposing additional operational burden. These measures, when implemented together, enhance adoption probability, mitigate regulatory and commercial risk, and accelerate the translation of diagnostic innovation into measurable patient benefit.

A rigorous, multi-source research methodology combining primary stakeholder engagement, clinical literature synthesis, regulatory mapping, and scenario analysis for robust insights

The research underpinning this analysis relies on a layered methodology that integrates primary stakeholder input, peer-reviewed clinical literature, regulatory documentation, and operational intelligence from diagnostic providers. Primary research included structured interviews with clinicians, laboratory directors, policy advisors, and procurement specialists to capture real-world workflow constraints, evidence expectations, and adoption barriers. Secondary sources comprised public regulatory filings, clinical guidelines, technology white papers, and recent academic publications to ground technical assessments and validate clinical utility claims.

Data were triangulated across sources to identify consistent themes and reconcile divergent perspectives. Scenario analysis evaluated supply-chain and tariff implications under alternative operational responses, while regulatory pathway mapping clarified approval and post-market obligations across major jurisdictions. Quality control measures included iterative expert review and validation of key inferences with domain specialists. Ethical considerations, including patient privacy and equitable access, informed interpretation of decentralized and at-home testing models. Together, these methodological elements ensured a balanced synthesis that links technological readiness to clinical, commercial, and policy realities.

A synthesis of diagnostic evolution showing how integrated technologies, evidence strategies, and operational resilience will determine clinical and commercial success

The evolution of breast cancer diagnostics and screening reflects both technological maturation and systemic realignment toward value-driven, patient-centered care. Imaging advances, molecular assays, digital pathology, and decentralized testing models are not isolated innovations but components of an integrated diagnostic ecosystem that supports earlier detection, more precise treatment selection, and efficient monitoring. Operational realities-regulatory expectations, reimbursement frameworks, and supply-chain resilience-will determine which technologies move from promising to pervasive.

Stakeholders that invest in rigorous evidence generation, flexible commercialization models, and resilient operational strategies will capture disproportionate clinical and commercial benefit. Equally important is alignment with regional policy priorities and provider workflows to ensure that diagnostics enhance, rather than complicate, care delivery. As the field advances, continuous collaboration between innovators, clinicians, payers, and regulators will be essential to translate technological potential into improved patient outcomes and system-level value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Offerings

  • 8.1. Digital Pathology
  • 8.2. Imaging Technologies
    • 8.2.1. Breast Ultrasound
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Mammography
  • 8.3. Implantable Sensors
  • 8.4. Liquid Biopsy
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarrays
    • 8.5.2. Next-Generation Sequencing
    • 8.5.3. PCR-Based Assays
  • 8.6. Wearable Devices

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Test Type

  • 9.1. Genetic Tests
    • 9.1.1. BRCA Testing
    • 9.1.2. Genomic Profiling
  • 9.2. Pathological Tests
    • 9.2.1. Cytology
    • 9.2.2. Histopathology
  • 9.3. Protein Marker Tests
    • 9.3.1. ER/PR Tests
    • 9.3.2. HER2 Tests

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by Stage

  • 10.1. Advanced Stage
    • 10.1.1. Stage III
    • 10.1.2. Stage IV
  • 10.2. Early Stage
    • 10.2.1. Stage I
    • 10.2.2. Stage II

11. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

  • 11.1. Early Detection
    • 11.1.1. Routine Mammograms
    • 11.1.2. Self-Exams
  • 11.2. Monitoring
    • 11.2.1. Recurrence
    • 11.2.2. Treatment Response
  • 11.3. Screening Programs

12. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Next-Generation Breast Cancer Diagnostic & Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next-Generation Breast Cancer Diagnostic & Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next-Generation Breast Cancer Diagnostic & Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Next-Generation Breast Cancer Diagnostic & Screening Market

17. China Next-Generation Breast Cancer Diagnostic & Screening Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agendia Inc.
  • 18.7. Agilent Technologies, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. BGI Genomics Co., Ltd.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Centogene N.V.
  • 18.12. Danaher Corporation
  • 18.13. Epic Sciences, Inc.
  • 18.14. Exact Sciences Corporation
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Fujifilm Holdings Corporation
  • 18.17. GE HealthCare Technologies, Inc.
  • 18.18. Hologic, Inc.
  • 18.19. Illumina, Inc.
  • 18.20. Invivoscribe, Inc.
  • 18.21. Koninklijke Philips N.V.
  • 18.22. Laboratory Corporation of America Holdings
  • 18.23. Merck & Co., Inc.
  • 18.24. Myriad Genetics, Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. Siemens Healthineers AG
  • 18.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (